摘要
目的分析标准剂量CEOP方案治疗老年非霍奇金淋巴瘤（NHL）患者的疗效和不良反应。方法回顾性分析福建省立医院2009年7月至2011年12月接受标准剂量CEOP方案±利妥昔单抗方案化疗的34例老年NHL患者的临床资料。B细胞淋巴瘤患者采用CEOP＋利妥昔单抗方案（环磷酰胺750mg／m2第1天，长春新碱2mg第1天，地塞米松10．15mg第1天至第5天，表柔吡星60～75mg／m2第1天，利妥昔单抗375mg／m2第0天，每周期间隔21～28d），T细胞淋巴瘤患者采用CEOP方案。结果34例患者完全缓解17例，部分缓解9例，稳定3例，进展5例，总有效率为76．5％（26／34）。主要不良反应为血液学毒性，Ⅲ～Ⅳ度粒细胞减少发生率为71．4％（24／34）。结论采用标准剂量CEOP方案治疗老年NHL疗效较高，心脏毒性较低，治疗耐受性良好，对一般状况良好的患者值得推荐。
Objective To study the efficacy and toxicity of standard CEOP regimen in elderly patients with non-Hodgkin＇s lymphoma （NHL）. Methods The study included 34 previously untreated patients, age 60 to 80 years old, with NHL, through July 2009 to December 2011. The patients with T-cell lyphoma received four to eight cycles of CEOP （cyelophosphamide 750 mg/m2 dl, epirubicin hydroehloride 60- 75 mg/m2 dl, vineristine 2rag dl, and dexamethasone 10-15 mg dl-5） every 3-4 weeks. Otherwise, the patient with B-cell lymphoma received R-CEOP, rituximab （375 mg/m2） was administered one day before CEOP. All the patients＂ clinical materials were collected and used to annalyze the efficacy and toxicity of the CEOP±R regimen. Results Among these 34 NHL patients, 17 cases reached CR, 9 cases reached PR, 3 cases remained SD, and 5 cases appeared PD. The total response rate was 76.5 %（26/34）. The major toxicity was bone marrow restraint. The rate of leukocyte decline with III-1V degree was 71.4 % （24/34）. Conclusion Using the standard regimen of CEOP leads to satisfied efficacy of elderly patients with NHL, and the toxcity is tolerant.
出处
《白血病．淋巴瘤》
CAS
2012年第12期739-741,共3页
Journal of Leukemia & Lymphoma
关键词
淋巴瘤
非霍奇金
抗肿瘤联合化疗方案
Lymphoma, non-Hodgkin＇s
Antineoplastie combined chemotherapy protocols
